Alnylam Pharmaceuticals
E100609
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Alnylam Pharmaceuticals canonical | 1 |
| Alnylam Pharmaceuticals Ireland | 1 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| collaboratesWith |
Novartis
ⓘ
Regeneron Pharmaceuticals ⓘ Roche ⓘ Sanofi ⓘ Vir Biotechnology ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
Amvuttra
ⓘ
Givlaari ⓘ Onpattro ⓘ Oxlumo ⓘ |
| focusesOn |
cardiometabolic diseases
ⓘ
central nervous system diseases ⓘ hepatic infectious diseases ⓘ rare genetic diseases ⓘ |
| foundedBy |
David Bartel
ⓘ
John Maraganore ⓘ Paul Schimmel ⓘ Phil Zamore ⓘ Phillip A. Sharp ⓘ Thomas Tuschl ⓘ |
| hasClinicalStagePrograms |
ATTR amyloidosis
ⓘ
cardiovascular disease ⓘ hemophilia ⓘ hypercholesterolemia ⓘ hypertension ⓘ |
| hasIndication |
acute hepatic porphyria
ⓘ
hereditary transthyretin-mediated amyloidosis ⓘ polyneuropathy of hereditary transthyretin-mediated amyloidosis ⓘ primary hyperoxaluria type 1 ⓘ |
| hasSubsidiary |
Alnylam Pharmaceuticals
self-linksurface differs
ⓘ
surface form:
Alnylam Pharmaceuticals Ireland
|
| headquartersLocation |
Cambridge, Massachusetts
ⓘ
surface form:
Cambridge, Massachusetts, United States
|
| inception | 2002 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn | NASDAQ ⓘ |
| missionStatement | to transform the lives of patients with RNAi therapeutics ⓘ |
| productType | RNAi therapeutic ⓘ |
| researchArea |
gene silencing
ⓘ
siRNA therapeutics ⓘ |
| specializesIn |
RNA interference therapeutics
ⓘ
RNAi-based drugs for genetically defined diseases ⓘ |
| targetOrgan | liver ⓘ |
| technologyPlatform | RNA interference ⓘ |
| tickerSymbol | ALNY ⓘ |
| usesDeliveryTechnology | GalNAc conjugate delivery ⓘ |
| website | https://www.alnylam.com ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Alnylam Pharmaceuticals Ireland